Vor Biopharma Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026New board members bring expertise and oversight; Zaccardelli led three pharma companies through acquisitions.
Equity plans affect how employees and leaders are rewarded; auditor selection ensures financial accuracy.
Drug approvals are major milestones that could lead to future revenue and patient access.
Quarterly reports show company spending, cash position, and progress on drug programs.
Registration statements let investors resell shares; part of fundraising agreements.
Annual reports reveal total revenue, losses, cash runway, and year-over-year progress.
New funding supports drug development; lower stock price of $14.05 shows market valuation.
Stocky reads Vor Biopharma Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Vor Biopharma Inc.'s most recent tracked filing was a 8-K on 7 Jul 2026: David Zaccardelli joins board as independent director.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.